The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2024

Filed:

Apr. 12, 2019
Applicant:

Institute of Biophysics Chinese Academy of Sciences, Beijing, CN;

Inventors:

Yangxin Fu, Beijing, CN;

Yong Liang, Beijing, CN;

Hua Peng, Beijing, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 14/555 (2006.01); C07K 14/56 (2006.01); C07K 14/565 (2006.01); C07K 14/57 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2827 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 38/217 (2013.01); A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 14/555 (2013.01); C07K 14/56 (2013.01); C07K 14/565 (2013.01); C07K 14/57 (2013.01); C07K 16/2818 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01);
Abstract

An IFN-anti-PD-L1 fusion protein, a pharmaceutical composition and a kit containing the same for treating tumors are disclosed. The IFN-anti-PD-L1 fusion protein of the present invention can simultaneously target PD-L1 and IFN receptors, and the activation of IFN signals in a tumor microenvironment (TME) can enhance the PD-1/PD-L1 therapy against tumors by inducing stronger T cell activation. The anti-PD-L1 antibody can be used to specifically deliver immunomodulatory molecules to tumor tissues, and the fusion protein results in the generation of multiple feedforward responses, which can increase the targeting effect, reduce the toxicity, and enhance the response to IFN therapy, thereby maximizing the anti-tumor effect.


Find Patent Forward Citations

Loading…